Behavioural Intervention
Cognitive Behavioral Therapy for Insomnia in Brain Tumor Patients
This trial aims to study a type of therapy called Cognitive Behavioral Therapy for Insomnia (CBT-I) in individuals with primary brain tumors who also have insomnia. The study will look at how feasible it
Monoclonal Antibodies
INCB7839 for Brain Cancer in Children
This trial tests INCB7839, a drug that blocks proteins helping cancer cells grow, on children with tough-to-treat brain tumors that have returned or grown after initial treatment. The drug works by stopping a protein needed for tumor growth from being released.
Kinase Inhibitor
Dabrafenib + Trametinib for Brain Tumors
This trial is studying the effects of two cancer medications, dabrafenib and trametinib, in children. These drugs work by stopping signals that make cancer cells grow. Dabrafenib and trametinib have shown benefits in various BRAF-mutant tumors, including melanoma, lung cancer, and thyroid cancer. The goal is to see how these treatments affect children over time.
Popular Filters
Trials for Brain Tumor Patients
PD-1 Inhibitor
ATRA + PD-1 Inhibitor for Brain Tumor
This trial tests a combination of a vitamin A derivative and an immune-boosting drug in patients with recurring brain tumors. The treatment aims to normalize cancer cell behavior and enhance the immune system's ability to fight the tumor.
Trials for IDH Positive Patients
PD-1 Inhibitor
ATRA + PD-1 Inhibitor for Brain Tumor
This trial tests a combination of a vitamin A derivative and an immune-boosting drug in patients with recurring brain tumors. The treatment aims to normalize cancer cell behavior and enhance the immune system's ability to fight the tumor.
Radiation Therapy
Pulsed Radiotherapy for Brain Cancer
This trial studies the side effects of a new method of giving radiation in small, timed doses, in patients with certain types of brain tumors who have had earlier treatments. This approach may be more effective and less harmful.
Trials With No Placebo
PD-1 Inhibitor
ATRA + PD-1 Inhibitor for Brain Tumor
This trial tests a combination of a vitamin A derivative and an immune-boosting drug in patients with recurring brain tumors. The treatment aims to normalize cancer cell behavior and enhance the immune system's ability to fight the tumor.
View More Related Trials
Frequently Asked Questions
Introduction to oligodendroglioma
What are the top hospitals conducting oligodendroglioma research?
Advancements in the understanding and treatment of oligodendroglioma, a rare type of brain tumor, are being made by top hospitals across the United States. One such institution making significant strides is Memorial Sloan Kettering Cancer Center in New york City. With six active clinical trials dedicated to this condition and a total of 11 conducted throughout their history, they have been at the forefront since recording their first trial in 2002. In Winston-Salem, North carolina, Wake Forest University Health Sciences is also actively involved in oligodendroglioma research with three ongoing trials and a notable nine completed studies since initiating their first trial in 2004.
Not too far away at Washington University School of Medicine in Saint Louis, Missouri, researchers are working diligently on three active oligodendroglioma trials alongside eight previous investigations which date back to their pioneering efforts starting from 2004. Meanwhile, M D Anderson Cancer Center located in Houston takes pride not only having achieved conducting present-day trio but has also marked its imprint with accomplishing just asmany past experiments dealing with this particular type of brain tumor; it all began for them back then around two decades ago.
Dana Farber Cancer Institute adds itself to this prestigious list as well with three ongoing clinical trials focused on oligodendroglioma along withinvolvement within five similar endeavors dated from year2005 onwards exclusively based out Boston's medical landscape.This collective effort among these renowned hospitals demonstrates commitment towards advancing knowledge about oligodendroglioma and improving outcomes for patients affected by this rare neurological disease that impacts individuals worldwide.
Which are the best cities for oligodendroglioma clinical trials?
The top cities for oligodendroglioma clinical trials are Boston, Houston, and New york. These cities have 9 active trials each that focus on various treatments such as rQNestin, dabrafenib, Proton Beam Radiation Therapy, INCB7839, and Pemigatinib. With a strong presence in research and development, these cities offer individuals with oligodendroglioma access to cutting-edge clinical trials that explore innovative treatment options and potentially contribute to advancements in care.
Which are the top treatments for oligodendroglioma being explored in clinical trials?
Oligodendroglioma, a rare form of brain tumor, is currently being targeted in clinical trials with several promising treatments. A pharmacological study takes the lead with two active trials and 11 all-time oligodendroglioma trials since its introduction in 2003. Another avenue of exploration involves combining cetuximab and bevacizumab through SIACI, showing potential in one ongoing trial that marks its debut on the scene in 2023. Additionally, craniotomy—a surgical procedure—holds promise as another treatment option under investigation with one active trial listed for oligodendroglioma. Finally, retifanlimab shows encouraging results as it enters the field with one ongoing trial following its first listing just last year (2022). As researchers delve deeper into these avenues for treating oligodendroglioma, there is hope for improved outcomes and an increased quality of life for patients facing this challenging diagnosis.
What are the most recent clinical trials for oligodendroglioma?
A multitude of recent clinical trials have emerged, bringing hope and potential advancements for individuals with oligodendroglioma. These trials include a phase 1 study exploring the effectiveness of low-dose OKN-007 administered twice daily, a single-arm trial investigating new treatment options specific to oligodendroglioma, and Phase 1 studies evaluating neural stem cells expressing CRAd-S-pk7 as well as surVaxM in patients who experienced relapse or progression. These groundbreaking endeavors provide promising prospects for improved outcomes in the management of oligodendroglioma.
What oligodendroglioma clinical trials were recently completed?
Recent advancements in oligodendroglioma clinical trials have brought hope for improved treatments. In January 2019, the National Cancer Institute wrapped up a trial investigating LB-100, demonstrating progress in understanding its potential against this complex brain tumor. Additionally, Northwestern University completed a trial in April 2017 examining neural stem cells loaded with an oncolytic adenovirus as a possible therapeutic approach. These milestones highlight ongoing efforts to address the challenges of oligodendroglioma and offer promising avenues for future research and treatment options.